TGF-β inhibitors
US12227508B2 · kind B2 · utility
0Cited by
10References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 7, 2022 |
| Grant date | Feb 18, 2025 |
| Priority date | — |
| Expiry date | Oct 7, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D519/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are pyrazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein A, X, Z, m, p, and R2 are as described herein. In certain embodiments, a compound disclosed herein inhibits the activity of one or more members of the TGF-β superfamily, and can be used to treat disease by blocking such activity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.